EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Peroxisome proliferator‐activated receptors as therapeutic target for cancer

Yuqing Wang iD, Feifei Lei, Yiyun Lin iD, Yuru Han, Lei Yang iD, Huabing Tan iD

Journal of Cellular and Molecular Medicine · 2024-03 · 28 (5)

DOI: 10.1111/jcmm.17931 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 12.09.2023. Verfasst von Yuqing Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Montefiore Medical Center, Wakefield Campus, Bronx, New York, USA. Hauptthemen laut MEDLINE: Neoplasms, Peroxisome Proliferator-Activated Receptors, Tumor Microenvironment. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator‐activated receptors (PPARs) are transcription factors belonging to the nuclear receptor family. There are three subtypes of PPARs, including PPAR‐α, PPAR‐β/δ and PPAR‐γ. They are expressed in different tissues and act by regulating the expression of target genes in the form of binding to ligands. Various subtypes of PPAR have been shown to have significant roles in a wide range of biological processes including lipid metabolism, body energy homeostasis, cell proliferation and differentiation, bone formation, tissue repair and remodelling. Recent studies have found that PPARs are closely related to tumours. They are involved in cancer cell growth, angiogenesis and tumour immune response, and are essential components in tumour progression and metastasis. As such, they have become a target for cancer therapy research. In this review, we discussed the current state of knowledge on the involvement of PPARs in cancer, including their role in tumourigenesis, the impact of PPARs in tumour microenvironment and the potential of using PPARs combinational therapy to treat cancer by targeting essential signal pathways, or as adjuvants to boost the effects of current chemo and immunotherapies. Our review highlights the complexity of PPARs in cancer and the need for a better understanding of the mechanism in order to design effective cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPeroxisome Proliferator-Activated ReceptorsTumor MicroenvironmentHumansAnimalsMolecular Targeted TherapySignal TransductionGene Expression Regulation, NeoplasticAntineoplastic Agents

Stichwörter der Autor:innen

PPARscancercombinational therapytherapeutic targetstumor microenvironment

Substanzen

Peroxisome Proliferator-Activated ReceptorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Montefiore Medical Center, Wakefield Campus, Bronx, New York, USA.
  • Department of Infectious Disease, Lab of Liver Disease, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
  • Department of Biomedical Sciences, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Qinghai Provincial People's Hospital, Xining, China.

ORCID-Profile: Yuqing Wang, Yiyun Lin, Lei Yang, Huabing Tan

Zitieren

APA

Wang, Y., Lei, F., Lin, Y., Han, Y., Yang, L., & Tan, H. (2024). Peroxisome proliferator‐activated receptors as therapeutic target for cancer. Journal of Cellular and Molecular Medicine, 28(5). https://doi.org/10.1111/jcmm.17931

Vancouver

Wang Y, Lei F, Lin Y, Han Y, Yang L, Tan H. Peroxisome proliferator‐activated receptors as therapeutic target for cancer. Journal of Cellular and Molecular Medicine. 2024;28(5). doi:10.1111/jcmm.17931

BibTeX
@article{Wang2024,
  author = {Wang, Yuqing and Lei, Feifei and Lin, Yiyun and Han, Yuru and Yang, Lei and Tan, Huabing},
  title = {Peroxisome proliferator‐activated receptors as therapeutic target for cancer},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  volume = {28},
  number = {5},
  doi = {10.1111/jcmm.17931}
}
Kostenlos starten →